

MTSCC like morphologic features. This case taught us the importance of considering the possibility of *ALK-RCC* in the pathological diagnosis of unusual renal tumors. So far, only 2 cases of *ALK*-rearranged RCC with MTSCC like features have been reported. Rarity of this tumor with limited data being published on this till now, further evokes an interest in this case.

ALK-RCCs usually express PAX 8, CK7, and vimentin, and no specific IHC marker other than *ALK*-IHC. Considering our *ALK-RCC* case morphologically resembling MTSCC with AMACR expression, we strongly recommend an analysis of *ALK* expression by IHC when diagnosing a renal tumor that mimics MTSCC.

CONCLUSION:

We have described a case of *ALK* rearranged -RCC which morphologically mimicked MTSCC. Since the use of molecular targeted therapy with an *ALK* inhibitor such as Alectinib and Crizotinib for cases of *ALK-RCC* is promising, the correct pathological diagnosis of *ALK-RCC* is quite important. Thus, we strongly recommend the routine performance of *ALK*-IHC in the pathological diagnosis of MTSCC.

REFERENCES:

1. Kuroda N, Sugawara E, Kusano H, Yuba Y, Yorita K, Takeuchi K. A review of *ALK*-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects. *Pol J Pathol*. 2018;69:109–13.
2. Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. 4th ed. Lyon, France: International Agency for Research on Cancer; 2016. p. 16–7.